Oncology Product Launch Plan and Execution for Rare Disease Indication

Achieving Product Launch Potential for Large Pharma




With the prevalence of cancers increasing, the treatment landscape has also shifted. Oncology drug launches are ever more critical and require a dedicated approach. For this reason, a large biotech and pharma company engaged Herspiegel Consulting for their product launch planning for a late oncology entrant in an established category.


The Problem


A biotech and large pharma company partnered with Herspiegel Consulting to commercialize a new oncology asset. The launch teams needed a cohesive launch plan reflecting all activities to be completed for launch readiness.


Our Solution


  • Herspiegel Consulting evolved a strawman product launch plan across functions to align to the asset development milestones, market opportunity and strategy.
  • Working sessions were facilitated with the alliance partners to review and finalize the launch plan by function, then a whole team review of the full plan and interdependencies was held.
  • Developed and tracked the risk and mitigation plan.
  • Established a governance process for product launches; managing project workstreams and teams to ensure rapid and seamless integration of internal and external stakeholders with timely updates to senior management.


Ocology Product Launch Graphs

Value Delivered


  • Launch strategies that offered proper direction to a team with competing priorities.
  • Clear and concise plans: delivered detailed strategy, key initiatives, and tactics ensuring alignment and coordination.
  • Successful product launches within a competitive market brand, exceeding revenue goals by ~25%.

Are you launching a new oncology product?

The oncology treatment landscape has shifted; we have experience in the oncology market and helping clients de-risk and accelerate product launches. Read our paper to learn more about our proven go-to-market model based on 75 pharmaceutical product launches.